Product Details
Synonym
CX3CL1, Fractalkine
Source
Biotinylated Human CX3CL1, His Tag, primary amine labeling (CX1-H8221) is expressed from human 293 cells (HEK293). It contains AA Gln 25 - Gln 341 (Accession # AAH01163). It is the biotinylated form of Human CX3CL1, His Tag (Cat. No. CX1-H5221).
Predicted N-terminus: Gln 25
Request for sequenceMolecular Characterization

Other Tags and Version Biotin & Other Labeled Version
This protein carries a polyhistidine tag at the C-terminus.
The protein has a calculated MW of 35.5 kDa. The protein migrates as 50-90 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Labeling
The primary amines in the side chains of lysine residues and the N-terminus of the protein are conjugated with biotins using standard chemical labeling method. A standard biotin reagent (13.5 angstroms) is used in this product.
Protein Ratio
Passed as determined by the HABA assay / binding ELISA.
Purity
>95% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
SDS-PAGE

Biotinylated Human CX3CL1, His Tag, primary amine labeling on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.
Customer Reviews Writing Reviews

Background
Recent Advances
- English Name:
C-X3-C motif chemokine ligand 1
- Category:
- Approved Drugs:
0 Details
- Drugs in Clinical Trials:
1 Details
- Highest Development Stage:
Phase 2 Clinical
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521



















